8-K: Day One Reports Strong OJEMDA Revenue, Reaffirms 2026 Outlook

Day One Biopharmaceuticals announced robust Q4 and full-year 2025 financial results, driven by strong OJEMDA sales, and reaffirmed its 2026 revenue guidance and pipeline progress.

Summary

• OJEMDA net product revenue reached $52.8 million for the fourth quarter and $155.4 million for the full year 2025.
• Full-year 2025 OJEMDA net product revenue represented 172% year-over-year growth, with double-digit sequential quarterly growth.
• Total OJEMDA prescriptions for 2025 were 4,635, marking 181% growth versus 2024 (April launch).
• The company reaffirmed its 2026 U.S. OJEMDA net product revenue guidance of $225 million to $250 million.
• Day One acquired Mersana Therapeutics in January 2026, adding Emi-Le, a B7-H4-directed ADC, to its pipeline, with Phase 1 data for adenoid cystic carcinoma (ACC) expected mid-2026.
• Updated three-year data from the pivotal Phase 2 FIREFLY-1 trial reinforced the durability of response and long-term safety profile of OJEMDA in relapsed or refractory pLGG patients.
• Enrollment in the pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in frontline pLGG remains on track, with full enrollment anticipated in the first half of 2026.
• The Phase 1a clinical trial of DAY301, a PTK7-targeted ADC, is progressing through dose escalation, with initial clinical data and a program update planned for the second half of 2026.
• Research and development expenses were $148.1 million for the full year 2025, down from $227.7 million in 2024.
• Selling, general and administrative expenses were $120.6 million for the full year 2025, up from $115.5 million in 2024.
• Net loss totaled $107.3 million for the full year 2025, compared to $95.5 million for the full year 2024.
• Cash, cash equivalents, and short-term investments totaled $441.1 million as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, highlighting exceptional commercial execution for OJEMDA and strategic pipeline expansion, which collectively position the company for sustained growth despite an increased net loss.

Positives

• Strong OJEMDA net product revenue growth: $155.4 million in FY 2025, a 172% year-over-year increase.
• Significant increase in OJEMDA prescription volumes: 4,635 total prescriptions in 2025, up 181% from 2024.
• Reaffirmed strong 2026 U.S. OJEMDA net product revenue guidance of $225 million to $250 million, representing over 50% growth at the midpoint.
• Positive three-year data from FIREFLY-1 trial for OJEMDA, showing durable responses, long-term safety, and a median time to next treatment of 42.6 months.
• Completion of enrollment for the pivotal Phase 3 FIREFLY-2 trial in frontline pLGG anticipated in 1H 2026, which could double the pLGG market opportunity.
• Strategic acquisition of Mersana Therapeutics in January 2026, expanding the pipeline with Emi-Le for adenoid cystic carcinoma (ACC), a high unmet need indication.
• Solid cash position of $441.1 million as of December 31, 2025.
• Research and development expenses decreased to $148.1 million in 2025 from $227.7 million in 2024, indicating potential efficiency or shift in development phase.

Negatives

• Increased net loss for the full year 2025 to $107.3 million from $95.5 million in 2024, despite revenue growth.
• Cash, cash equivalents, and short-term investments decreased to $441.1 million from $531.7 million at December 31, 2024.
• Selling, general and administrative expenses increased to $120.6 million in 2025 from $115.5 million in 2024.
• License revenue significantly decreased to $2.8 million in 2025 from $73.9 million in 2024, primarily due to the 2024 sale of a Priority Review Voucher.

Risks

• Ability to grow revenue from OJEMDA.
• Plans to develop and commercialize cancer therapies and pipeline, including Emi-Le and DAY301.
• Risks related to the ability to realize anticipated benefits of the Mersana acquisition, including integration challenges, difficulty maintaining business relationships, negative effects on stock price/operating results, significant transaction costs, and unknown liabilities.
• Ability to develop, obtain, and retain regulatory approval for or commercialize any product candidate.
• Ability to protect intellectual property.
• Potential impact of global business or macroeconomic conditions, including as a result of inflation, government shutdowns, rising interest rates, instability in the global banking system, and geopolitical conflicts.
• Sufficiency of cash, cash equivalents, and investments to fund operations.

Future Outlook

Day One Biopharmaceuticals projects U.S. OJEMDA net product revenue of $225 million to $250 million for 2026, representing over 50% growth at the midpoint compared to 2025. The company anticipates completing enrollment for the pivotal Phase 3 FIREFLY-2 trial in frontline pLGG in the first half of 2026, with topline data expected mid-2027, potentially leading to approval in 2028. Updated Phase 1 clinical data for Emi-Le is expected mid-2026, and initial Phase 1a data for DAY301 is planned for the second half of 2026. An EMA regulatory decision for tovorafenib is also expected in 2026.

Management Comments

• "2025 was a seminal year for Day One, marked by significant achievements across every pillar of our organization." Jeremy Bender, Ph.D., chief executive officer.
• "By maintaining our strong commercial execution, leveraging our expertise to extend into additional rare cancers, and steadily advancing our early-stage pipeline, we are delivering on our mission to bring new medicines to people of all ages with life-threatening diseases." Jeremy Bender, Ph.D., chief executive officer.
• "The commercial momentum we've established for OJEMDA and the important upcoming clinical data updates across our full pipeline position us for strong growth in 2026 and beyond." Jeremy Bender, Ph.D., chief executive officer.

Industry Context

StockSavvy.ai notes that Day One's strong commercial performance for OJEMDA in pediatric low-grade glioma (pLGG) positions it as a significant player in the rare pediatric oncology market. The acquisition of Mersana Therapeutics and its B7-H4-directed ADC, Emi-Le, for adenoid cystic carcinoma (ACC) demonstrates a strategic expansion into other high-unmet-need rare cancers, aligning with a broader industry trend of biopharmaceutical companies seeking to diversify their pipelines with targeted therapies for niche indications. The focus on ADCs (Emi-Le, DAY301) also reflects the growing interest and investment in this modality across the oncology landscape, with companies like Seagen (now part of Pfizer) and Daiichi Sankyo having set high benchmarks for ADC development and commercial success.

Comparison to Industry Standards

• OJEMDA's 172% year-over-year revenue growth and 181% prescription growth in its first full year post-launch (April 2024 approval) are exceptionally strong for a new oncology therapeutic, particularly in a rare disease indication like pLGG. This performance compares favorably to the typical ramp-up of novel therapies, which often face slower initial adoption.
• The median duration of response of 19.4 months and median time to next treatment of 42.6 months for OJEMDA in relapsed/refractory pLGG from the FIREFLY-1 trial are highly competitive, demonstrating significant clinical benefit in a patient population with limited options. For instance, other targeted therapies in rare pediatric cancers, such as Vitrakvi (larotrectinib) for TRK fusion cancers, have shown durable responses, and OJEMDA's data aligns with the high efficacy expected from precision oncology drugs.
• The strategic acquisition of Emi-Le for adenoid cystic carcinoma (ACC) positions Day One in a market with an annual U.S. incidence of ~1,300 patients, similar in scale to other rare cancer indications pursued by companies like Blueprint Medicines (e.g., for gastrointestinal stromal tumors) or Loxo Oncology (now Eli Lilly) for various precision oncology targets.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reaffirmed guidance, pipeline expansion, and positive clinical data, suggesting potential for increased shareholder value.
• Patients: Positive impact through continued access to OJEMDA for pLGG and potential new therapies (Emi-Le, DAY301) for other life-threatening cancers.
• Employees: Potential for growth and stability within the company due to commercial success and pipeline advancements.
• Healthcare Providers: Reinforcement of OJEMDA as a standard of care in relapsed/refractory pLGG, providing a reliable treatment option.

Next Steps

• Management participation in 46th Annual TD Cowen Health Care Conference on March 3, 2026.
• Management presentation at 2026 Leerink Partners Global Healthcare Conference on March 11, 2026.
• Complete FIREFLY-2 trial enrollment in 1H 2026.
• Tovorafenib EMA regulatory decision in 2026.
• Deliver Phase 1 clinical data for Emi-Le by mid-2026.
• Report Phase 1 updates from DAY301 and inform next development steps in 2H 2026.
• Topline data from FIREFLY-2 trial expected mid-2027.
• Potential approval for OJEMDA in frontline pLGG in 2028.

Key Dates

Recommendation

The filing demonstrates exceptional commercial momentum for OJEMDA, significantly exceeding expectations for a rare disease drug launch. The reaffirmed strong 2026 revenue guidance, coupled with positive long-term clinical data for OJEMDA and strategic pipeline expansion through the Mersana acquisition, indicates robust future growth potential. While the net loss increased, it is typical for a growing biopharmaceutical company investing in R&D and commercialization. The strong cash position provides a solid runway. These factors collectively suggest a compelling investment opportunity.

Keywords

Biopharmaceuticals, Oncology, Pediatric Cancer, pLGG, OJEMDA, Tovorafenib, BRAF, ADC, Emi-Le, DAY301, Adenoid Cystic Carcinoma, Financial Results, SEC Filing, DAWN, Clinical Trials, Pipeline, Mersana Therapeutics